Safety and efficacy of glucagon-like peptide-1 receptor agonists in children and adolescents with obesity: A meta-analysis by Ryan, Paul M. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Safety and efficacy of glucagon-like peptide-1 receptor agonists in
children and adolescents with obesity: A meta-analysis
Author(s) Ryan, Paul M.; Seltzer, Sean; Hayward, Nathaniel E.; Avelar Rodriguez,
David; Sless, Ryan T.; Hawkes, Colin P.
Publication date 2021-05-11
Original citation Ryan, P. M., Seltzer, S., Hayward, N. E., Avelar Rodriguez, D., Sless, R.
T. and Hawkes, C. P. (2021) 'Safety and efficacy of glucagon-like
peptide-1 receptor agonists in children and adolescents with obesity: A
meta-analysis', Journal of Pediatrics, 236 , pp. 137-147. doi:
10.1016/j.jpeds.2021.05.009




Access to the full text of the published version may require a
subscription.
Rights © 2021, the Authors. Published by Elsevier inc. This is an open
access article distributed under the terms and conditions of the






Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in
Children and Adolescents with Obesity: A Meta-Analysis
Paul M. Ryan, MB, BCh, BAO, PhD1, Sean Seltzer, MB, BCh, BAO, MSc2, Nathaniel E. Hayward, MB, BCh, BAO, MSc3,
David Avelar Rodriguez, MD4, Ryan T. Sless, MB, BCh, BAO, MSc5, and Colin P. Hawkes, MD, PhD1,6,7
Objectives To determine the weight, body mass index (BMI), cardiometabolic, and gastrointestinal effects of
glucagon-like peptide-1 (GLP-1) receptor agonists in children with obesity.
Study designWeb of Science, PubMed/MEDLINE, and Scopus databases from 01/01/1994-01/01/2021 for ran-
domized control trials examining the weight, BMI, cardiometabolic, or gastrointestinal effects of GLP-1 receptor ag-
onists in children and adolescents with obesity. Data were extracted by 2 independent surveyors and a random
effects model was applied to meta-analyze generic inverse variance outcomes. Primary outcomes were related
to weight and cardiometabolic profile, and secondary outcomes of interest were gastrointestinal-related treat-
ment-emergent adverse events.
Results Nine studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved lir-
aglutide. GLP-1 receptor agonists use caused a modest reduction in body weight (mean difference [MD] -1.50
[-2.50,-0.50] kg, I2 64%), BMI (MD -1.24 [-1.71,-0.77] kg/m2, I2 0%), and BMI z score (MD -0.14 [-0.23,-0.06], I2
43%). Glycemic control was improved in children with proven insulin resistance (glycated hemoglobin A1c MD
-1.05 [-1.93,-0.18] %, I2 76%). Although no lipid profile improvements were noted, a modest decrease in systolic
blood pressure was detected (MD -2.30 [-4.11,-0.49] mm Hg; I2 0%). Finally, analysis of gastrointestinal-related
treatment-emergent adverse events revealed an increased risk of nausea (risk ratio 2.11 [1.44, 3.09]; I2 0%), without
significant increases in other gastrointestinal symptoms.
Conclusions This meta-analysis indicates that GLP-1 receptor agonists are safe and effective in modestly
reducing weight, BMI, glycated hemoglobin A1c, and systolic blood pressure in children and adolescents with
obesity in a clinical setting, albeit with increased rates of nausea. (J Pediatr 2021;236:137-47).
PROSPERO ID CRD42020195869.
P
revalence of pediatric obesity is approaching 1 in 5 children and adolescents age 2-19 years in the US.1 As a direct conse-
quence of this obesity surge, we will continue to experience a substantial adult cardiometabolic burden.2 Public health
measures to optimize lifestyle (ie, dietary/exercise) interventions and to reduce culpable environmental exposures are
the primary target for governments and societies.3 There remains a subset of children and adolescents whose obesity is resistant
to this approach.4 For these children, and particularly those with severe obesity, pediatricians have little to offer in terms of safe,
effective, and durable weight-reducing pharmaceutical interventions with high-grade evidence supporting their use.4,5
Incretins are gut-derived hormones, such as glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
(GLP-1), which have been shown to confer a range of beneficial metabolism-regulating functions, ranging from increased in-
sulin secretion and sensitivity to delayed gastric emptying and promotion of postprandial satiety.6,7 Two discrete classes of
incretin-based therapies have arisen, namely GLP-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors
(DPP-4Is). Although these medication classes were designed and licensed
initially for their antihyperglycemic effects, they have demonstrated weight regu-
lating and cardioprotective potential in clinical trials involving adults.8,9
Research exploring the efficacy of these drugs in pediatric obesity has been
accumulating over the past decade. The first drug of the class, Saxenda (liraglu-
tide), received Food and Drug Administration approval for use in children age
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12-17 years with obesity (weight >60 kg and BMI of >30 kg/
m2 in accordance with international standards10/³95th
percentile) in 2020. However, as these trials have generally
been of small or modest size, the precise cardiometabolic ef-
fects and associated safety of GLP-1RAs has not been
adequately established in the pediatric setting. The present
systematic review and meta-analysis aimed to assess whether
GLP-1RAs reduce weight or body mass index (BMI) and
improve cardiometabolic profile, defined here as improve-
ment in glycated hemoglobin A1c (HbA1c), lipid profile, or
blood pressure in children with obesity when compared
with placebo or no intervention in a randomized controlled
trial (RCT). As a secondary aim, we sought to determine if
GLP-1RAs are associated with increased gastrointestinal
side effects, pancreatitis, and altered liver function in the
same population.
Methods
The design and reporting of the present systematic review
andmeta-analysis follows the PRISMA guidelines.11 A proto-
col for this meta-analysis was prospectively registered
(PROSPERO ID: CRD42020195869).12
The literature was comprehensively searched through the
Web of Science, PubMed/MEDLINE, and Scopus databases
from January 1, 1995 to January 1, 2021 using the strategies
outlined in Table I (available at www.jpeds.com) by means
of the University College Cork library system. All resulting
references were uploaded to the Covidence Systematic
Review Manager platform (covidence.org) for screening
and data extraction purposes.
We originally aimed to include all clinical trials that
explored the use of GLP-1RA (eg, exenatide, lixisenatide, du-
laglutide, and liraglutide) or DPP-4I (eg, sitagliptin, vilda-
gliptin, saxagliptin, and linagliptin) in male and/or female
children and adolescents age <18 years at time of randomiza-
tion with obesity (mean age-adapted BMI >30 kg/m2), with
or without a diagnosis of type 2 diabetes (T2D). However,
as no trials examining the use of DPP-4Is were uncovered,
they will not be further discussed in this review. Only RCTs
were included in the ultimate quantitative meta-analysis.
Studies including participants with type 1 diabetes, obesity-
associated genetic disorders (eg, Prader-Willi syndrome), hy-
pothyroidism, or any history of an eating disorder were
excluded from the present systematic review and meta-
analysis. The authors functioned in 2 distinct and indepen-
dent working groups of screeners who reviewed each abstract
and/or full text manuscript in duplicate to ensure relevance
and appropriate data reporting. Reference lists of included
studies were reviewed for potential additional studies of rele-
vance. Any discrepancies in inclusion/exclusion decisions
were resolved through discussion and consensus with a third
party.
As with screening, data extraction was conducted in dupli-
cate by 2 independent authors from the working groups out-
lined above. Details on the baseline characteristics and
demographics of the study population, as well as information
on the study group and funders were collected. A range of
outcomes were extracted for time points at the beginning
and at intervention end. The primary outcomes for quantita-
tive meta-analysis were cardiometabolic in nature, including
reductions in body weight/BMI/z score, HbA1c, fasting
plasma glucose, lipid profile (triglycerides, total cholesterol,
low-density cholesterol [LDL-C]), and blood pressure attrib-
utable to the intervention. Secondary outcomes of interest
related to rates of gastrointestinal-related treatment-emer-
gent adverse events (TEAEs), such as nausea, vomiting, diar-
rhea, abdominal pain, and elevated pancreatic enzymes.
The generic inverse variance mean difference (MD) or risk
ratios (RR) with 95% CIs representing the effect of GLP-
1RAs on outcomes of interest at the longest follow-up point
were produced using a random-effects DerSimonian and
Laird model. This method incorporates adjustment for het-
erogeneity of intervention effects between the studies
included and was applied given the potentially high degree
of heterogeneity across pediatric study populations. Sub-
group analyses exploring the effect of specific medication
on the weight and BMI z score reducing capacity and
TEAE rates of the interventions were also performed. Hetero-
geneity among results was evaluated using the Cochran Q test
and the I2 test. RevMan v 5.4 (Review Manager; The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014) was
used to conduct all statistical analyses.
Although not specified in the registered protocol a priori,
it was deemed appropriate to conduct a sensitivity analysis
exploring the effect of concurrent lifestyle interventions on
the therapeutic effect of the medications given the presence
of such adjuncts in several of the trials.
The risk of bias tool was applied to each study included by
2 independent reviewers through the Covidence platform.
The overall study risk of bias assessment was used to provide
context when discussing the relevant primary and secondary
outcomes. Finally, funnel plots were generated and visually
assessed, and Egger tests were conducted to explore any po-
tential publication bias.
Results
In total, 737 references were uncovered through the search
strategy outlined, of which 72 were removed as duplicates
(Figure 1; available at www.jpeds.com). Subsequent
abstract screening of the remaining 665 references resulted
in exclusion of all but 10 studies. Review of the respective
references lists revealed an additional 2 references of
relevance. Following full text review, 9 studies of relevance
to the research question remained, of which 2 were post-
hoc analyses of data already included, and 1 was not a
clinical trial. Finally, all 9 of these studies were randomized
controlled trials reporting outcomes of interest in a useable
manner and were, therefore, included in the meta-analysis.
Of the 9 studies included, 3 were conducted in the US,13-15
1 in Germany,16 1 in Sweden,17 1 in China,18 and 3 were
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international consortia19-21 at sites in countries including
Belgium, Mexico, Russia, Slovenia, Sweden, the United
Kingdom, and the US, among others (Table II; available at
www.jpeds.com). Although 8 of the studies were parallel
RCTs,13,14,16-21 1 study used a crossover RCT design.15 In
terms of the therapeutic intervention, 3 studies involved
exenatide14,15,17 and 6 involved liraglutide.13,16,19,20 All
studies reported the use of a volume-matched placebo
injection pen, and 3 of the included studies explicitly
reported the application of concurrent lifestyle
interventions for both the intervention and placebo
groups.15,18,20
In total, this meta-analysis included data from 574 chil-
dren and adolescents, 302 of which received a GLP-1RA.
The majority of the studies were small in size, ranging from
11 to 44 participants, and short in duration, ranging from
5 to 26 weeks (Table III).13-17,19 However, 2 of the studies
were relatively large in scale and duration, involving 134
and 251 participants in 52- and 56-week-long
interventions, respectively.20,21 The mean (SD) age across
all included participants was 14.15 (2.16) years, with a
slight female (53.3%) majority. Mean weights of
participants at baseline ranged from 71.5 kg to 124 kg, with
BMI ranging from 33.9 to 43 kg/m2 and BMI z score from
2.9 to 3.9. Although all studies included children with
obesity or severe obesity, only 3 of the studies exclusively
included participants with T2D or prediabetes,18,19,21
although diagnosis of T2D was not an exclusion criterion
for the remainder of studies.
Of the 3 trials which explored exenatide, 1 applied a dose of
2mcg daily for the duration of intervention,17 and the other 2
commenced at 5 mcg daily and escalated to 10 mcg after
1 month.14,15 In the other 6 trials, which applied liraglutide,
1 commenced at 0.3 mg daily and escalated gradually up
to 1.8 mg,19 1 commenced at 0.3 mg daily and escalated
up to 3 mg,13 1 commenced at 0.6 mg daily and escalated
up to 1.2 mg,18 1 commenced at 0.6 mg and escalated to
1.8 mg,21 and 2 commenced at 0.6 mg daily and escalated
up to 3 mg.16,20 Although 82.4% and 92.9% of liraglutide-
treated participants reached the maximum daily dosage in
Kelly et al20 and Mastrandrea et al,13 respectively, just
55.6% of participants reached the maximum dose of 1.8 mg
in Tamborlane et al because of the dosing guidelines.21
Among the included studies, GLP-1RA use resulted in a
modest reduction in body weight (MD 1.50 [-2.50, -0.50]
kg, I2 64%), BMI (MD -1.24 [-1.71, -0.77] kg/m2, I2 0%),
and BMI z score (MD -0.14 [-0.23, -0.06], I2 43%)
(Figure 2). Subsequent subgroup analyses by the specific
medication revealed no discernable difference in the body
weight reducing effects of exenatide (MD -2.02 [-4.54,
0.49] kg, I2 72%) when compared with liraglutide (MD
-1.51 [-2.85, -0.17] kg, I2 67%), with a subgroup
heterogeneity I2 of 0%. Similarly, BMI reductions were
indistinguishable between exenatide (MD -1.11 [-1.67,
-0.55] kg/m2, I2 0%) and liraglutide (MD -1.58 [-2.42,
-0.70] kg/m2, I2 0%), with a subgroup heterogeneity I2 also
of 0%. Finally, BMI z score reduction was similar between
exenatide (MD -0.09 [-0.18, 0.00]) and liraglutide (MD
-0.17 [-0.28, -0.06], I2 43%), with a subgroup heterogeneity
I2 of 16.4% (Figure 2).
A sensitivity analysis exploring the effect of concurrent
lifestyle intervention, provided to both control and interven-
tion arms, on weight and BMI outcomes revealed the adjunc-
tive therapy to be highly complementary to GLP-1RA
treatment (Figure 3; available at www.jpeds.com). This was
true for weight reduction, which improved from an MD of
-0.76 kg (-1.43, -0.09; I2 29%) without lifestyle intervention
to -4.25 kg (-6.31, -2.20; I2 0%) with lifestyle intervention
(subgroup heterogeneity I2 90.1%). Similarly, BMI
reduction was improved from an MD of -0.97 kg/m2
(-1.59, -0.35; I2 0%) without lifestyle intervention to
-1.60 kg/m2 (-2.32, -0.88; I2 0%) with lifestyle intervention
(subgroup heterogeneity I2 41.1%). Finally, BMI z score
was reduced by an MD of -0.13 (-0.22, -0.03; I2 45%)
without lifestyle intervention, but -0.22 (-0.37, -0.07) with
lifestyle MD (subgroup heterogeneity I2 6.2%). An
additional sensitivity analysis exploring the effects
separating normoglycemic populations from those with
prediabetes or T2D did not reveal a significant effect of
population insulin resistance status on GLP-1RA weight,
BMI or BMI z score reducing capacity (Figure 4; available
at www.jpeds.com).
Among the 6 studies that reportedHbA1c, GLP-1RA inter-
vention only had an effect on populations which were exclu-
sively composed of children with insulin resistance (ie, T2D
or prediabetes: MD -1.05 [-1.93, -0.18] %, I2 76%), and no
Table III. Included studies baseline population characteristics
Studies
Author year
Study population demographics and baseline data
n Mean age y (SD) Male n (%) White % Black % Other % Mean weight (kg) Mean BMI (kg/m2) BMI z score
Kelly et al 201215 11 12.7 (2.1) 2 (18.2) NR NR NR 93.8 37 NR
Kelly et al 201314 26 15.2 (1.8) 10 (38.5) 76.9 15.4 7.7 124 43 NR
Klein et al 201419 21 15 (NR) 7 (33.3) 66.7 33.3 0 113 40 3.4
Danne et al 201716 21 14.9 (1.3) 7 (33.3) NR NR NR 105.5 36 3.2
Mastrandrea et al 201913 24 9.9 (1.1) 15 (62.5) 58.3 41.7 37.5 71.5 NR 3.9
Kelly et al 202020 251 14.6 (1.6) 102 (40.6) 83.7 8 8.3 100.8 36 3.17
Weghuber et al 202017 44 14.4 (2.3) 22 (50) 93.2 2.3 4.5 104.4 36 3.2
Tamborlane et al 201921 134 14.6 (1.7) 51 (38.1) 64.9 11.9 23.2 91.5 33.9 2.94
Zhou et al 201718 42 11.16 (2.2) 29 (69) NR NR NR NR 30.94 NR
NR, not reported.
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Figure 2. Forrest plot of mean difference change in weight, BMI, and BMI z score following GLP-1 receptor agonist intervention
in children with obesity. Studies are subgrouped by the specific intervention.
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effect was detected in those which included mixed popula-
tions (MD -0.08 [-0.13, 0.02] %, I2 0%; subgroup heteroge-
neity I2 79%) (Figure 5). However, no effect on fasting
plasma glucose was noted for either population (insulin
resistance: MD -16.26 [-41.23, 8.71] mg/dL, I2 76%; mixed
population: MD -1.76 [-3.51, 0.01] mg/dL, I2 0%). In the 3
studies that explored lipid profile following intervention,
no improvements in total cholesterol (MD -4.17 [-11.29,
2.95] mg/dL; I2 39%), LDL-C (MD -4.63 [-10.25, 0.98] mg/
dL; I2 0%), or triglycerides (MD 1.24 [-10.47, 12.96] mg/
dL; I2 0%) were noted (Figure 6). Finally, despite no effect
on DBP among the 4 studies reporting blood pressure (MD
0.28 [-1.39, 1.94] mm Hg, I2 13%), a modest decrease in
systolic blood pressure was detected (MD -2.30 [-4.11,
-0.49] mm Hg; I2 0%) (Figure 6).
Of the studies where liraglutide was used, the most
commonly affected systems for TEAEs were gastrointestinal
(GI), skin and subcutaneous tissue (6.3-14.3 per 100 partic-
ipants), neurologic (18.8-50 per 100 participants), endocrine,
and hepatobiliary (Table IV; available at www.jpeds.com).
The most common endocrine TEAE was hypoglycemia
(14.3-25 per 100 participants), and the singular
hepatobiliary TEAE was elevated transaminases (0-7.1 per
100 participants). For the 3 studies assessing exenatide, the
Figure 5. Forrest plot of mean difference change in glycemic control following GLP-1 receptor agonist intervention in children
with obesity. Studies are subgrouped according to their exclusive inclusion of children and adolescents with some degree of
insulin resistance (ie, T2D or prediabetes) or not (ie, mixed population). FPG, fasting plasma glucose.
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Figure 6. Forrest plot of mean difference change in cardiovascular parameters following GLP-1 receptor agonist intervention in
children with obesity. SBP, systolic blood pressure; DBP, diastolic blood pressure.
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primary system implicated in TEAEs was also GI. The most
common GI TEAEs were nausea (36.4-62.0 per 100
participants), vomiting (27.3-31 per 100 participants), and
abdominal pain (15-18.2 per 100 participants) with
diarrhea being reported in a single study (8 per 100
participants).
Of the GI-related TEAEs, a significantly increased risk of
nausea (RR 2.11 [1.44, 3.09]; I2 0%) (Figure 7) was
described, and although there was a greater risk of diarrhea
(RR 1.66 [0.91, 3.04]; I2 0%), vomiting (RR 1.65 [0.71,
3.85]; I2 30%), and abdominal pain (RR 1.32 [0.73, 2.39];
I2 0%) in the GLP-1RAs groups, none of these were found
to be statistically significant. No significant difference was
noted between the 2 medications for RR of nausea
(exenatide RR 2.17 [0.79, 5.95]; I2 18%; liraglutide RR 2.49
[1.35, 4.59]; I2 0%) or abdominal pain (exenatide RR 7
[0.40, 121.39]; liraglutide RR 1.22 [0.66, 2.24]; I2 0%;
subgroup heterogeneity I2 0%).
All studies in liraglutide-treated children reported on
pancreatic enzymes,13,16,19-21 bar 1.18 Danne et al reported
1 participant who was found to have elevated amylase and
lipase, and 1 with isolated elevated lipase following liraglutide
initiation. Klein et al noted no effect on amylase, but 3 in-
stances of marginally elevated lipase following liraglutide
treatment (all less than twice the upper limit of normal).19
Similarly, Tamborlane et al found higher levels of lipase in
the blood of treated children at both 26 and 52 weeks of inter-
vention (treatment ratio 1.11 [1.01, 1.23]).21 Although Mas-
trandrea et al noted increased mean levels of both lipase and
amylase in their liraglutide-treated group13; however, they
deemed these to be clinically inconsequential as all cases
were under 3 times the upper limit of normal. A single case
of pancreatitis, which was moderate in severity and resolved
without intervention, was reported amongst all liraglutide-
treated participants.20 No pancreatic enzyme or pancreatitis
data was reported for exenatide.
Calcitonin levels, which may alert investigators to any
cases of medullary thyroid cancer, were assessed by 4 of
the studies concerning liraglutide and reported as
normal.13,16,19,21 No studies exploring exenatide reported
on calcitonin levels.
In general, the studies included in this review were deemed
to be at a low risk of performance, detection, and reporting
bias; although several were represented as unclear and 2
studies were deemed at high risk of performance bias,15,18
owing to their open-label designs (Figure 8; available at
www.jpeds.com). Just 3 of the 9 studies reported specific
random sequence generation and allocation concealment
methods.17,20 Concerning attrition rates placed 5 out of the
9 studies at a significant risk of bias,13-15,17,20 as determined
by the predefined cut-off of >13% or overtly uneven losses.
Several studies were classed as unclear or high risk of bias
due to their modest participant size or sort intervention
duration. Because of the relatively low number of studies
included in the present meta-analysis, it was not possible to
perform the Egger test for the synthesized data; however,
visual inspection of funnel plots resulted in low concern for
publication bias (Figure 9; available at www.jpeds.com).
Discussion
Our systematic review of the literature revealed 8 RCTs and 1
crossover RCT, involving a total of 574 participants with a
mean age of ~14 years and baseline BMI ranging from 33.9
to 43.0 kg/m2. Ultimately, we found that GLP-1RAs confer
a modest but clear blood pressure, HbA1c, and weight
reducing effect, the latter of which is complimented by
concurrent lifestyle intervention, with relatively minor,
predominantly GI, side effects.
In the present meta-analysis, GLP-1RAs demonstrated
weight-reducing effects; however, in contrast to what has
been established in adult populations, there was no difference
noted in the efficacy of liraglutide and exenatide in this
population.22 Although these were the only 2 compounds
for which pediatric data are available, trials are ongoing with
more novel iterations of GLP-1RAs (eg, clinicaltrials.gov ID:
NCT04102189). As per the National Institute for Health and
Care Excellence guidelines, obesity prevention and lifestyle
weight management interventions, including instructive exer-
cise and nutritional education, promotion of healthy options,
and behavioral counseling, represent the mainstay of obesity
management in children.23 Although these interventions can
be highly effective in certain individuals in the correct setting,
they have their clear limitations (eg, patient and carer engage-
ment) and may benefit from adjunctive approaches or thera-
pies. In line with this, we found lifestyle interventions to be
complementary in amplifying the weight-reducing effects of
GLP-1RAs in children with obesity. Indeed, this has been
demonstrated previously in adult populations,24 and research
into the anti-obesity potential of GLP-1RAs appears to be
continuing in this direction,25 for example in the Semaglutide
Treatment Effect in People with obesity (STEP) trials.26,27
GLP-1RAs were originally designed and distributed for
their effects on glycemic control, with reductions in HbA1c
of 1.48% and 1.28% in the Diabetes Therapy Utilization:
Researching Changes in A1C, Weight and Other Factors
Through Intervention with Exenatide Once Weekly
(DURATION)-6 trial for liraglutide and exenatide,
respectively.22 In our subgroup analysis which separated
studies that exclusively included participants with proven
insulin resistance frommixed population studies, we demon-
strated a significant effect of GLP-1RA on the HbA1c only in
the former group. However, this is to be expected as such
therapies are unlikely to display corrective effects in
individuals without suboptimal baseline glycemic control.
Indeed, the effect size was comparable with adult data, with
a reduction of 1.05% in the insulin resistant subgroup.
In a similar manner to weight reduction, the hypocholes-
terolemic and cardioprotective effects of GLP-1RAs became
clear soon after the antihyperglycemic effects were
established.28 Since this point, virtually all of the established
and approved GLP-1RA medications have been assessed for
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Figure 7. Forrest plot of risk ratios for gastrointestinal treatment emergent adverse events associated with GLP-1 receptor
agonist intervention in children with obesity. Studies are subgrouped by the specific intervention.
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their cardioprotective capacity in a large phase III RCT,29-32
with several novel compounds currently under assessment
(clinicaltrials.gov ID: NCT03496298). However, all of the
above trials have been focused on adults with T2D and
significant cardiovascular risk factors or comorbidities.
Although the pediatric studies included in this analysis did
not set out to explore the effects of such medications on
cardiovascular-related outcomes such as lipid profile and
blood pressure, these outcomes were reported. Although
there were no notable effects on total cholesterol, LDL-C,
or triglycerides, these outcomes were generally within normal
ranges or at the upper end of normal at baseline, suggesting
that there was little scope for reduction. This may explain
the absent or minimal effect noted in this study when
compared with similar adult studies.33 Nevertheless, we did
note a significant reduction in systolic blood pressure, which
may be of clinical importance when considered in the context
of life-long hypertension in children with additional
cardiovascular risk factors.
One of the major concerns which initially arose around
GLP-1RA use was a perceived increased rate of pancreatitis
and pancreatic cancer.34 However, in the 5 liraglutide studies,
which examined pancreatic enzymes in the present
analysis,13,16,19-21 lipase and amylase were elevated in only a
handful of cases and all but 1 case were deemed to be at
clinically inconsequential levels. Ultimately, a single
episode of acute pancreatitis was detected amongst all
liraglutide-treated participants.20 This is in keeping with
the current knowledge, as several meta-analyses of
GLP-1RA trials involving patients with T2D35-37 and
cardiovascular risk factors35 have repeatedly revealed no
increased risk of either pathology. Similarly, an increased
risk of medullary thyroid cancer with GLP-1RA use has
been theorized as a result of rodent data38; however, no
such effect was detected in the 4 liraglutide studies that
examined calcitonin levels included in this meta-analysis.
This is also in keeping with the results of larger adult trials.39
Anti-obesity therapies must be tolerable to facilitate
compliance and subsequent efficacy.40,41 This is of particular
relevance considering the GI-related TEAEs, which have
previously been attributed to the GLP-1RAs. Indeed, several
notes of concern were registered with the editor regarding the
effects of such TEAEs on nutrient intake42 and absorption43
in children following the recent study by Kelly et al.20
However, although we found an increase RR of nausea events
in the present meta-analysis, we observed no such significant
increased risk for other potentially concerning GI symptoms
such as vomiting, diarrhea, or abdominal pain. In keeping
with this, previous reports have shown that liraglutide exerts
satiating effects that appear to be entirely uncoupled from the
GI-related TEAEs.44 Together, these data suggest that
GLP-1RAs are generally safe to use in children who will be
monitored for local and systemic symptoms, as well as GI
side effects.
The study is limited by the relatively low number of trials
uncovered, as well as the fact that 1 study contributed
approximately one-half of the participants for the
meta-analysis. In addition, more than one-half of the
included trials were of a short duration (ie, <3 months),
which may ultimately underestimate the potential effect
size of such therapies. Moreover, the relatively large
proportion of participants with concomitant T2D may
have introduced a degree of heterogeneity in the estimated
weight-reducing efficacy, although this was not detected in
subgroup analysis. Similarly, the diversity of dosage regimens
and the variability in their implementation success may
represent a further source of heterogeneity that must be
considered. Although no publication bias could be detected,
a number of the studies exceeded the predefined acceptable
attrition rate and therefore represented a high risk of bias.
Nevertheless, confidence in the primary outcome can be
gained from the homogeneity displayed within the
meta-analyses.
This meta-analysis revealed GLP-1RAs to be effective in
reducing weight, HbA1c, and blood pressure in children
and adolescents with obesity or severe obesity. In addition,
this weight-reducing effect appears to be bolstered by
concurrent lifestyle intervention. A modest decrease in
systolic blood pressure was also identified. Finally, apart
from increased rates of minor GI-related symptoms such as
nausea, no serious TEAEs were noted. Ultimately, this
meta-analysis indicates that GLP-1RAs are safe, tolerable,
and effective in improving cardiometabolic profile in
children with obesity. n
We express our gratitude to Dr Paula Hale, Senior Medical Director of
Novo Nordisk Inc, for provision of several data points of relevance to
this meta-analysis.
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50 Years Ago in THE JOURNAL OF PEDIATRICS
Parenteral Nutrition of the Small Premature Infant
Benda G, Babson S. Peripheral intravenous alimentation of the small premature infant. J Pediatr 1971;79:494-98.
Parenteral nutrition refers to intravenous nourishment to provide the main energy and total nutrition source for aninfant that cannot be fed (for any clinical condition) or as a complementary therapy to enteral feeding.
In The Journal 50 years ago, Benda and Babson described the indications, features, and advantages in the concern of
parenteral nutrition for small premature infants. They highlighted the importance of establishing a source of nutri-
tional support for premature infants to provide them enough nutrients for appropriate growth and development,
optimal weight gain, and survival improvement.
Since the publication of this report, we have seen a continual increase in scientific evidence about the nutritional
role that parenteral nutrition plays and the estimated energy requirements to satisfy healthy growth and development
in these infants.1 This specifically includes studies that evaluated the optimal infusion rate, the best route of admin-
istration, the advantages, risks, and more importantly, a detailed assessment of each of the nutritional components.
This data has allowed the development of standardized nutritional formulas based on scientific recommendations.
In the ensuring 50 years, valuable information, based on scientific evidence, validates its use and efficacy (enhancing
growth rates, reducing mortality, and optimizing neurocognitive development).
In future studies, it will be important to continually reassess the guidelines that determine the way most practi-
tioners administer parenteral nutrition. This will be aided by additional information about the optimal composition
of neonatal intravenous nutrition, the adverse effects, the safety of providing early and aggressive intravenous com-
ponents (lipids, proteins, carbohydrates, and trace elements), as well as the optimal time to initiate their supplemen-
tation.
Since publication of this review, 2 particular statements remain true: the early initiation of nutritional support is an
important step in achieving appropriate growth and this manner can reduce the mortality rate in premature infants.
Josselyn Hernandez Perez, MD
Tecnolgico de Monterrey School of Medicine Monterrey
Nuevo Leon, Mexico
Reference
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Figure 1. PRISMA flowchart of study search, screening,
inclusion, and synthesis counts.
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Figure 3. Sensitivity analysis exploring the effects of adjunctive lifestyle interventions on the weight, BMI, and BMI z score
reducing efficacy of GLP-1 receptor agonist intervention in children with obesity.
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Figure 4. Subgroup analysis exploring the effects of insulin resistance on the weight, BMI, and BMI z score reducing Efficacy of
GLP-1 receptor agonist intervention in children with obesity.
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Figure 8. Risk of bias assessment. A, Summary of risk of bias scores across categories; B, Breakdown of risk of bias
assessment across individual studies.
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Figure 9. Detection of publication bias. Funnel plots of synthesized studies for parameters including A,weight,B,BMI,C, BMI z
score, D, HbA1c, E, fasting plasma glucose, F, total cholesterol, G, LDL-C, H, triglycerides, I, SBP, and J, DBP. SBP, systolic
blood pressure; DBP, diastolic blood pressure.
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Table I. Database search strategies and results
Databases Strategy Result
SCOPUS (TITLE-ABS-KEY ( “Obesity” OR “Obese” OR “Overweight”) AND TITLE-ABS-KEY
(“Children” OR “Child” OR “Pa*diatric” OR “Boy” OR “Girl” OR “Adolescent” OR
“Teen”) AND TITLE-ABS-KEY (“glucagon-like peptide-1 receptor agonists” OR “GLP-
1RA” OR “Exenatide” OR “Lixisenatide” OR “Dulaglutide” OR “Liraglutide” OR
“dipeptidyl peptidase-4 inhibitors” OR “DPP-4i” OR “Sitagliptin” OR “Vildagliptin” OR
“Saxagliptin” OR “Linagliptin”) AND TITLE-ABS-KEY (“Intervention Studies” OR
“intervention” OR “controlled trial” OR “randomized” OR “randomised” OR “random”
OR “randomly” OR “placebo” OR “assignment” OR “trial”) ) AND PUBYEAR > 1994
312
WEB OF SCIENCE (“Obesity” OR “Obese” OR “Overweight”) AND TOPIC: (“Children” OR “Child” OR
“Pa*diatric” OR “Boy” OR “Girl” OR “Adolescent” OR “Teen”) AND TOPIC: (“glucagon-
like peptide-1 receptor agonists” OR “GLP-1RA” OR “Exenatide” OR “Lixisenatide” OR
“Dulaglutide” OR “Liraglutide” OR “dipeptidyl peptidase-4 inhibitors” OR “DPP-4i” OR
“Sitagliptin” OR “Vildagliptin” OR “Saxagliptin” OR “Linagliptin”) AND TOPIC:
(“Intervention Studies” OR “intervention” OR “controlled trial” OR “randomized” OR
“randomised” OR “random” OR “randomly” OR “placebo” OR “assignment” OR
“trial")
51
MEDLINE AB (“Obesity” OR “Obese” OR “Overweight”) AND AB (“Children” OR “Child” OR
“Pa*diatric” OR “Boy” OR “Girl” OR “Adolescent” OR “Teen”) AND AB (“glucagon-like
peptide-1 receptor agonists” OR “GLP-1RA” OR “Exenatide” OR “Lixisenatide” OR
“Dulaglutide” OR “Liraglutide” OR “dipeptidyl peptidase-4 inhibitors” OR “DPP-4i” OR
“Sitagliptin” OR “Vildagliptin” OR “Saxagliptin” OR “Linagliptin”) AND AB
(“Intervention Studies” OR “intervention” OR “controlled trial” OR “randomized” OR
“randomised” OR “random” OR “randomly” OR “placebo” OR “assignment” OR
“trial”)
374
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Intervention Control Dose regimen Country Setting Design Sponsorship source












initiated at a dose of 5
mcg twice daily
subcutaneously. Up
titrated to 10 mcg
twice daily after 1 mo
for the remainder of
the trial. If the 10 mcg
dose was not tolerated,






Crossover RCT Minnesota Obesity Center (NIH grant
P30DK050456 NORC) and GCRC
(M01-RR00400, General Clinical
Research Center Program, NCRR/NIH).
Glucose meters donated by Bayer
HealthCare.
Kelly et al 201314 13 wk Volume-matched
placebo pen
Initiated at 5 mcg twice
daily. After 1 mo, up
titrated to 10 mcg





RCT Community Health Collaborative
grant from the University of
Minnesota Clinical and Translational
Science Institute, by award
1UL1RR033183 from the National
Center for Research Resources, and
by grant 8UL1TR000114-02 from
the National Center for Advancing
Translational Sciences of the National
Institutes of Health.
Exenatide
Klein et al 201419 5 wk Volume-matched
placebo pen
Initiated at 0.3 mg daily
for first wk and
increased weekly
thereafter to 0.6 mg,









Danne et al 201716 5 wk Volume-matched
placebo pen
Initiated at 0.6 mg daily,
and the dose was
increased by 0.6 mg/











Initiated at 0.3 mg daily.
Dose was escalated
from 0.3 to 1.2 mg in
weekly increments of
0.3 mg and then
followed with 0.6 mg
weekly increments to a
maximum dose of
3.0 mg or maximum
tolerated dose.
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Sweden Not specified RCT Regional Research Council in Uppsala-
Orebro, Sweden, the Swedish Diabetes
Foundation, the Swedish Society for












Initiated at a dose of
0.6 mg per d. The dose
was increased in 0.6-
mg increments to a
maximum dose of
1.8 mg per d.










Initial dose was 0.6 mg
daily. After 1 wk,
adjusted to 1.2 mg/













































































































Table IV. Treatment emergent adverse events and potential side-effect of GLP-1RAs in children with obesity
Studies
Author year TEAE Group/dose (mg) Number of participants (n) Proportion of participants (%) Total events (n)
Klein et al 201419 Hypoglycemia 0.6 3 25 4
Liraglutide Hypoglycemia Placebo 0 0 0
Diarrhea 0.3 3 21.4 3
Diarrhea 0.6 3 25 3
Diarrhea 0.9 0 0 0
Diarrhea 1.2 0 0 0
Diarrhea 1.8 1 11.1 1
Diarrhea Placebo 1 14.3 1
Nausea 0.3 3 21.4 3
Nausea 0.6 0 0 0
Nausea 0.9 0 0 0
Nausea 1.2 0 0 0
Nausea 1.8 1 11.1 1
Nausea Placebo 1 14.3 1
Vomiting 0.3 0 0 0
Vomiting 0.6 1 8.3 1
Vomiting 0.9 1 11.1 1
Vomiting 1.2 0 0 0
Vomiting 1.8 0 0 0
Vomiting Placebo 2 26.3 3
Kelly et al 201215 Nausea 10 mcg 4 36.36
Exenatide Vomiting 3 27.27
Headache 3 27.27
Abdominal pain – mild 2 18.18
Abdominal pain – moderate 1 9.09
Injection site bruising 1 9.09
Danne et al 201716 Nausea 0.6-3 mg 7 50 11
Liraglutide Nausea Placebo 0 0 0
Vomiting 0.6-3 mg 4 28.6 4
Vomiting Placebo 0 0 0
Diarrhea 0.6-3 mg 3 21.4 3
Diarrhea Placebo 0 0 0
Abdominal pain 0.6-3 mg 4 28.6 12
Abdominal pain Placebo 0 0 0
Upper abdominal pain 0.6-3 mg 2 14.3 2
Upper abdominal pain Placebo 0 0 0
Distension 0.6-3 mg 1 7.1 1
Distension Placebo 0 0 0
Abdominal wall hematoma 0.6-3 mg 1 7.1 1
Abdominal wall hematoma Placebo 0 0 0
Injection site pain 0.6-3 mg 3 21.4 5
Injection site pain Placebo 0 0 0
Injection site pruritus 0.6-3 mg 1 7.1 1
Injection site pruritus Placebo 0 0 0
Transaminase elevation 0.6-3 mg 1 7.1 1
Transaminase elevation Placebo 0 0 0
Alopecia 0.6-3 mg 1 7.1 1
Alopecia Placebo 0 0 0
Hematoma 0.6-3 mg 1 7.1 1
Hematoma Placebo 0 0 0
Hypoglycemic episodes 0.6-3 mg 2 14.3 3
Hypoglycemic episodes Placebo 0 0 0
Nervous system disorders 0.6-3 mg 7 50 13
Nervous system disorders Placebo 1 14.3 1
Infection 0.6-3 mg 6 42.9 6
Infection Placebo 2 28.6 2
MSK 0.6-3 mg 3 21.4 3
MSK Placebo 0 0 0
Reproductive system/breast disorders 0.6-3 mg 3 21.4 3
Reproductive system/breast disorders Placebo 0 0 0
Respiratory and mediastinal 0.6-3 mg 2 14.3 5
Respiratory and mediastinal Placebo 1 14.3 1
Skin and subcutaneous 0.6-3 mg 2 14.3 2
Skin and subcutaneous Placebo 0 0 0
Injury and procedural complications 0.6-3 mg 1 7.1 1
Injury and procedural complications Placebo 0 0 0
Vascular disorders 0.6-3 mg 1 7.1 2
Vascular disorders Placebo 0 0 0
Mastrandrea et al 201913 GI 0.3-3 mg 6 37.5 19
(continued )
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Table IV. Continued
Studies
Author year TEAE Group/dose (mg) Number of participants (n) Proportion of participants (%) Total events (n)
Liraglutide GI Placebo 1 12.5 1
Nausea 0.3-3 mg 2 12.5 2
Nausea Placebo 0 0 0
Vomiting 0.3-3 mg 4 25 5
Vomiting Placebo 0 0 0
Diarrhea 0.3-3 mg 1 6.3 1
Diarrhea Placebo 0 0 0
Abdominal pain upper 0.3-3 mg 1 6.3 5
Abdominal pain upper Placebo 0 0 0
Dyspepsia 0.3-3 mg 0 0 0
Dyspepsia Placebo 1 12.5 1
Salivary hypersecretion 0.3-3 mg 1 6.3 1
Salivary hypersecretion Placebo 0 0 0
Headache 0.3-3 mg 2 12.5 2
Headache Placebo 0 0 0
Dizziness 0.3-3 mg 1 6.3 1
Dizziness Placebo 0 0 0
Injection site induration 0.3-3 mg 2 12.5 2
Injection site induration Placebo 0 0 0
Injection site reaction 0.3-3 mg 1 6.3 1
Injection site reaction Placebo 0 0 0
Orbital edema 0.3-3 mg 1 6.3 1
Orbital edema Placebo 0 0 0
Increased ALT 0.3-3 mg 0 0 0
Increased ALT Placebo 1 12.5 1
Nervous system disorders 0.3-3 mg 3 18.8 4
Nervous system disorders Placebo 4 50 5
General and site conditions 0.3-3 mg 3 18.8 4
General and site conditions Placebo 1 12.5 1
Infection 0.3-3 mg 2 12.5 2
Infection Placebo 1 12.5 1
MSK 0.3-3 mg 1 6.3 1
MSK Placebo 1 12.5 2
Respiratory and mediastinal 0.3-3 mg 2 12.5 4
Respiratory and mediastinal Placebo 0 0 0
Ear 0.3-3 mg 1 6.3 1
Ear Placebo 0 0 0
Eye 0.3-3 mg 1 6.3 1
Eye Placebo 0 0 0
Injury and procedural complications 0.3-3 mg 0 0 0
Injury and procedural complications Placebo 1 12.5 1
Skin and subcutaneous 0.3-3 mg 1 6.3 1
Skin and subcutaneous Placebo 0 0 0
Hypoglycemic episodes 0.3-3 mg 4 25 5
Hypoglycemic episodes Placebo 1 12.5 1
Weghuber et al 202017 GI 2 mg
(continued )
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Author year TEAE Group/dose (mg) Number of participants (n) Proportion of participants (%) Total events (n)
Exenatide GI Placebo
Nervous system disorders 2 mg 1 72.7
Nervous system disorders Placebo 1 59.1
General and site conditions 2 mg 1 50
General and site conditions Placebo 9 40.9
Infection 2 mg 1 81.8
Infection Placebo 2 90.9
MSK 2 mg 5 22.7
MSK Placebo 6 27.3
Respiratory and mediastinal 2 mg 8 36.4
Respiratory and mediastinal Placebo 8 36.4
Ear 2 mg 2 9.1
Ear Placebo 0 0
Eye 2 mg 1 4.6
Eye Placebo 1 4.6
Injury and procedural complications 2 mg 5 22.7
Injury and procedural complications Placebo 3 13.6
Skin and subcutaneous 2 mg 5 22.7
Skin and subcutaneous Placebo 1 4.6
Hypoglycemic episodes 2 mg 0 0
Hypoglycemic episodes Placebo 0 0
Blood and lymph 2 mg 0 0
Blood and lymph Placebo 2 9.1
Endocrine disorders 2 mg 1 4.6
Endocrine disorders Placebo 0 0
Immune system disorders 2 mg 1 4.6
Immune system disorders Placebo 0 0
Metabolism and nutrition 2 mg 2 9.1
Metabolism and nutrition Placebo 2 9.1
Psychiatric disorders 2 mg 1 4.6
Psychiatric disorders Placebo 2 9.1
Renal and urinary disorders 2 mg 2 9.1
Renal and urinary disorders Placebo 0 0
Reproductive system and breast 2 mg 5 22.7
Reproductive system and breast Placebo 1 4.6
Social 2 mg 1 4.6
Social Placebo 0 0
Kelly et al 202020 Nausea 0.6-3 mg 5 42.4 101
(continued )
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Table IV. Continued
Studies
Author year TEAE Group/dose (mg) Number of participants (n) Proportion of participants (%) Total events (n)
Liraglutide Nausea Placebo 1 14.3 25
Vomiting 0.6-3 mg 4 34.4 85
Vomiting Placebo 5 4 8
Diarrhea 0.6-3 mg 2 22.4 44
Diarrhea Placebo 1 14.3 29
Abdominal pain upper 0.6-3 mg 1 13.6 25
Abdominal pain upper Placebo 1 13.5 23
Abdominal pain 0.6-3 mg 1 8 15
Abdominal pain Placebo 1 8.7 15
URTI 0.6-3 mg 1 8.8 14
URTI Placebo 1 8.7 16
Nasopharyngitis 0.6-3 mg 3 27.2 68
Nasopharyngitis Placebo 3 30.2 80
Headache 0.6-3 mg 2 23.2 43
Headache Placebo 3 27.8 53
Oropharyngeal pain 0.6-3 mg 1 8.8 11
Oropharyngeal pain Placebo 1 11.9 18
Influenza 0.6-3 mg 1 8.8 11
Influenza Placebo 1 9.5 12
Gastroenteritis 0.6-3 mg 1 12.8 22
Gastroenteritis Placebo 6 4.8 9
Pyrexia 0.6-3 mg 1 8 11
Pyrexia Placebo 9 7.1 11
Dizziness 0.6-3 mg 1 10.4 15
Dizziness Placebo 4 3.2 5
Dysmenorrhea 0.6-3 mg 4 3.2 5
Dysmenorrhea Placebo 8 6.3 16
Arthralgia 0.6-3 mg 3 2.4 3
Arthralgia Placebo 8 6.3 8
Pharyngitis 0.6-3 mg 4 3.2 5
Pharyngitis Placebo 7 5.6 7
Hypoglycemia 0.6-3 mg 2 0 0
Hypoglycemia Placebo 1 0 0
Kelly et al 201314 Nausea 10-20 mcg 62
Exenatide Nausea Placebo 31
Abdominal pain 10-20 mcg 15
Abdominal pain Placebo 23
Diarrhea 10-20 mcg 8
Diarrhea Placebo 31
Headache 10-20 mcg 23
Headache Placebo 46
Vomiting 10-20 mcg 31
Vomiting Placebo 8
Hypoglycemia 10-20 mcg 0
Hypoglycemia Placebo 0
Tamborlane et al 201921 Nausea 0.6-1.8 mg 19 28.8 25
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Author year TEAE Group/dose (mg) Number of participants (n) Proportion of participants (%) Total events (n)
Liraglutide Nausea Placebo 9 13.2 12
Vomiting 0.6-1.8 mg 17 25.8 46
Vomiting Placebo 6 8.8 8
Diarrhea 0.6-1.8 mg 15 22.7 22
Diarrhea Placebo 11 16.2 13
Headache 0.6-1.8 mg 14 21.2 27
Headache Placebo 13 19.1 39
Abdominal pain 0.6-1.8 mg 12 18.2 23
Abdominal pain Placebo 5 7.4 6
Nasopaharyngitis 0.6-1.8 mg 11 16.7 16
Nasopaharyngitis Placebo 19 27.9 28
Dizziness 0.6-1.8 mg 8 12.1 10
Dizziness Placebo 2 2.9 4
Gastroenteritis 0.6-1.8 mg 7 10.6 8
Gastroenteritis Placebo 2 2.9 2
URTI 0.6-1.8 mg 6 9.1 10
URTI Placebo 5 7.4 8
Dyspepsia 0.6-1.8 mg 5 7.6 6
Dyspepsia Placebo 1 1.5 1
Rash 0.6-1.8 mg 4 6.1 5
Rash Placebo 1 1.5 1
Pyrexia 0.6-1.8 mg 4 6.1 5
Pyrexia Placebo 5 7.4 5
Decreased appetite 0.6-1.8 mg 4 6.1 4
Decreased appetite Placebo 3 4.4 3
Constipation 0.6-1.8 mg 4 6.1 4
Constipation Placebo 1 1.5 1
Dysmenorrhea 0.6-1.8 mg 3 4.5 10
Dysmenorrhea Placebo 6 8.8 11
Upper abdominal pain 0.6-1.8 mg 2 3 3
Upper abdominal pain Placebo 8 11.8 9
Increased alanine aminotransferase 0.6-1.8 mg 0 0 0
Increased alanine aminotransferase Placebo 4 5.9 5
Hypoglycemia 0.6-1.8 mg 30 45.5 160
Hypoglycemia Placebo 17 25 63
ALT, alanine aminotransferase; URTI, upper respiratory tract infection; MSK, musculoskeletal.
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